Empagliflozin decreases remnant‐like particle cholesterol in type 2 diabetes patients with insulin resistance
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims/Introduction: Remnant lipoproteins are thought to be atherogenic. Remnant‐like particle cholesterol (RLP‐C), which reflects the levels of various kinds of remnant lipoproteins in the blood, has a significant correlation with insulin resistance. Materials and Methods: In the present study, we measured the effect of empagliflozin (EMPA) on the levels of RLP‐C, and investigated whether EMPA‐mediated change in RLP‐C is associated with a change in insulin resistance in type 2 diabetes patients who have insulin resistance. Results: Patients were allocated to receive a placebo (n = 51) or EMPA (n = 58) as an add‐on treatment. Fasting blood samples were collected before and 12 weeks after this intervention. EMPA significantly decreased glycated hemoglobin, bodyweight, systolic blood pressure, plasma triglycerides, liver transaminases and estimated glomerular filtration rate, and increased high‐density lipoprotein cholesterol. Furthermore, EMPA decreased RLP‐C and homeostatic model assessment of insulin resistance. In the placebo group, there were no significant changes in these factors except for slight increases in liver transaminases. Multiple regression analysis showed that the change in homeostatic model assessment of insulin resistance (P = 0.0102) and the change in alanine aminotransferase (P = 0.0301) were significantly associated with the change in RLP‐C in the EMPA group. The change in RLP‐C significantly correlated with the change in homeostatic model assessment of insulin resistance (Pearson correlation coefficient 0.503, 95% confidence interval 0.199–0.719; P = 0.00241). Conclusion: EMPA decreases RLP‐C levels, which is closely associated with amelioration of insulin sensitivity in diabetes patients who have insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Kugiyama, K., Doi, H., Takazoe, K., Kawano, H., Soejima, H., Mizuno, Y., Tsunoda, R., Sakamoto, T., Nakano, T., Nakajima, K., et al. (1999) · Circulation · doi:10.1161/01.cir.99.22.2858 · Cited by 284
Cited by
Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 308
Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications
Donate-Correa, J., Ferri, C. M., Sánchez-Quintana, F., Pérez-Castro, A., González-Luis, A., Martín-Núñez, E., Mora-Fernández, C., & Navarro-González, J. F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.628289 · Cited by 140
Coelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
“Most studies (n 1⁄4 16) were double‐blinded; four had an open‐labelled design.(35,40,47,56) Regarding quality assessment, nine studies were considered of Good Quality by the Cochrane Collaboration's risk of bias assessment tool while the remaining eleven were considered of Fair Quality.”
BackgroundQin, Z., Zhou, K., Li, Y.-P., Wang, J.-L., Cheng, W.-J., Hu, C.-P., Shi, C., He, H., & Zhou, Y.-J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0819-z · Cited by 56
Dorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., Rodríguez-Tamez, G., Barrera-Flores, F. J., Farrell, A. M., Montori, V. M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01103-9 · Cited by 39
Metadata
- Authors
- Hattori, S.
- Venue
- Journal of Diabetes Investigation
- Publisher
- Wiley
- Published
- 2017-12-27
- Volume
- 9
- Issue
- 4
- Pages
- 870-874
- ISSN
- 2040-1116 (ISSN-L)
- 2040-1124
- OpenAlex
- W2770289206
- Cited by
- 37
- References
- 5
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.